immatics raises €34m series-D financing round

As part of the transaction terms, immatics will initially receive a €12m tranche of funding. 

The latest round will be used to complete the development of the firm's lead vaccine IMA901, a cancer vaccine that comprises 10 tumor-associated peptides (TUMAP), which are usually found in the majority of patients suffering from renal cell carcinoma (RCC).

Other investors in the latest financing round include existing backer dievini Hopp Biotech holding, a life sciences investor, and family office AT Impf.

immatics first received private equity funding in 2004, according to unquote" data. In immatics' first financing round, 3i, Wellington Partners, Merifin Capital, L-EA Private Equity and Grazia Private Equity backed the firm with an estimated €14m, received across two tranches: immatics received an initial tranche of around €8m in 2004, while one year later exisiting investors were joined by Vinci Capital as immatics received the second tranche of approximately €5-6m.

In 2007, immatics raised €40m from new investor KfW as well as existing backers 3i and Wellington Partners. The financial investors had no plans for further funding rounds and intended to list the firm by 2009, according to unquote" data.

The firm then received a €53.8m series-C funding round led by MIG in 2010.

Company
immatics is based in Tübingen and Martinsried, where it employs 70 staff. It initially span out of the University of Tübingen.

The pharmaceutical firm is currently developing its lead product, IMA901, which is in a phase-3 study.

The vaccine successfully completed the phase-2 study, with the result that RCC patients who produced an immune response to two or more of the TUMAPs contained in IMA901 lived significantly longer.

People
Peter Chambré is chairman of immatics' board. Paul Higham is CEO of immatics. Erich Schlick and Rainer Strohmenger worked on the deal for Wellington in 2010. Matthias Kromayer is head of the life sciences department at MIG.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Germany
• Wellington Partners